Resources for You
Caprelsa (vandetanib) Tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
- Intestinal perforation occurred in 0.4% of CAPRELSA treated patients versus 0% of placebo treated
Clinical Studies Experience
- Table 1 - Adverse Reactions With a ≥ 5% Increased Incidence in Patients on Caprelsa Compared to Placebo During Randomized Treatment: Updated and additions made.